Innovative Pulsed Low Dose Rate Chemoradiation Significantly Lowers Side Effects in Cancer Treatment
A cutting-edge pulsed low dose rate chemoradiation therapy has shown promise in reducing side effects for esophageal and lung cancer patients, maintaining treatment effectiveness while improving patient comfort.
Researchers at Fox Chase Cancer Center have demonstrated that a novel approach called pulsed low dose rate (PLDR) chemoradiation therapy can effectively reduce treatment-related side effects in patients with esophageal and non-small cell lung cancers, without compromising the efficacy of the cancer therapy. This breakthrough was presented during the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO).
The phase I clinical trial involved 39 patients with locally advanced disease—35 with esophageal cancer and 4 with non-small cell lung cancer—who received standard chemotherapy combined with PLDR radiation over a span of 5.5 to 6 weeks. The key advantage of PLDR is its ability to deliver radiation in short pulses separated by a few minutes, allowing healthy tissues to repair DNA damage between doses. This method helps to minimize damage to surrounding healthy tissue compared to traditional radiation methods.
Dr. Joshua Meyer, Vice Chair of Translational Research at Fox Chase, explained that the traditional challenge has been severe side effects such as esophagitis, which causes pain and swallowing difficulties, often requiring feeding tubes or IV hydration. The study results revealed that severe esophagitis occurred in only 26% of patients, a significant reduction from the typical 40% seen with conventional treatments. Moreover, the patients experienced a median overall survival of approximately 45 months, and a notable portion achieved complete or near-complete responses when followed by surgery.
The technical success of PLDR lies in its pacing; it maintains treatment intensity while sparing healthy tissue. The approach was pioneered at Fox Chase by Dr. Chang-Ming Charlie Ma, who developed the methodology for optimal delivery.
This research indicates that PLDR could become a valuable first-line treatment option for certain cancers, reducing adverse effects and improving patient quality of life, while maintaining strong treatment outcomes. Further studies are underway to validate these findings and expand its application.
Source: https://medicalxpress.com/news/2025-09-pulsed-dose-chemoradiation-therapy-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Only 36.4% of U.S. Adults Are Free of Cardiovascular Disease Risk Factors in Recent Years
A recent study shows that only 36.4% of U.S. adults had no cardiovascular disease risk factors from August 2021 to 2023, highlighting ongoing challenges in cardiovascular health and prevention.
Potential Risks of BPA Alternatives in Food Packaging on Ovarian Cell Functions
New research highlights potential risks of BPA substitute chemicals in food packaging disrupting ovarian cell functions, raising concerns over unregulated chemical use and consumer safety.
Early and Sustained LDL-C Reduction with Inclisiran in High-Risk Cardiovascular Patients
A new clinical trial shows that inclisiran safely and effectively lowers LDL cholesterol levels early and sustainably in patients at high cardiovascular risk, improving outcomes and reducing adverse muscle symptoms.
Lithuanian Researchers Develop Innovative System for Post-Stroke Patient Monitoring
Lithuanian scientists have developed an advanced system for integrated post-stroke monitoring, enhancing long-term patient care through synchronized physiological measurements. This innovative technology aims to improve outcomes and manage neurological and cardiovascular health more effectively.